Articles
-
Burden of cerebral adrenoleukodystrophy on affected children and their families through the eyes of family caregivers
Rare Dis Orphan Drugs J 2022;2:17. DOI: 10.20517/rdodj.2022.13AbstractAim: This research assessed the needs of family caregivers of children with cerebral adrenoleukodystrophy (cALD), ... MOREAim: This research assessed the needs of family caregivers of children with cerebral adrenoleukodystrophy (cALD), focusing on the diagnostic process; the burden of the disease on the child and their caregiver’s quality of life; and the physical, social, psychological, professional, and financial impacts on the whole family.Methods: Family caregivers of children with cALD were recruited via the European Leukodystrophies Association International’s online platform, Leuconnect, to respond to a quantitative survey and a quality-of-life questionnaire and participate in a qualitative semi-structured interview. The questions focused on disease experience from onset to diagnosis and consequences on current life. Twelve family caregivers of 14 children were interviewed.Results: cALD diagnosis took an average of 16.5 months, and 8 of 12 children were misdiagnosed, with parents often describing a lack of listening from doctors. Caregivers described bedridden children whose poor quality of life correlated with a high Neurologic Function Score. On average, they needed to care for their children 7.7 h/day, with serious consequences for their employment, social life, and psychological state.Conclusion: Our interviews with family caregivers helped us to consider limiting diagnostic wandering by improving the skills of general practitioners and public knowledge of pathology. By gathering information on precise daily routines centered around a dependent child, we can better understand how to effectively support families by adapting not only the global care of the child but also to the following needs expressed for the entire family: better information, coordination of both care and administrative procedures, and real respite. LESS Full articleOriginal Article|Published on: 30 Dec 2022 -
The discovery of the Papillon-Lefèvre syndrome, a rare cathepsin C related lysosomal disease
Rare Dis Orphan Drugs J 2022;2:16. DOI: 10.20517/rdodj.2022.26Editorial|Published on: 27 Dec 2022 -
Targeting neutrophil serine proteinases in alpha-1 antitrypsin deficiency
Rare Dis Orphan Drugs J 2022;1:15. DOI: 10.20517/rdodj.2022.18AbstractAlpha-1 antitrypsin (AAT) is the most abundant irreversible serine proteinase inhibitor in the circulation and ... MOREAlpha-1 antitrypsin (AAT) is the most abundant irreversible serine proteinase inhibitor in the circulation and plays a major role in protecting lung tissue against destruction from neutrophil serine proteinases. Genetic mutation of AAT leads to reduced circulating levels and AAT deficiency (AATD) which is associated with an increased risk of developing emphysema. This observation suggests that the balance between AAT and neutrophil serine proteinase is crucial in maintaining tissue homoeostasis. In AATD, the overexuberant proteinase activity resulting from inadequate AAT control creates a self-perpetuating inflammatory cycle, driving progressive tissue injury. Re-establishing this physiological balance is therefore critical for preserving lung architecture, function, and abrogating disease progression.Several avenues within this pathophysiological pathway are being explored. This chapter addresses the pathophysiological process, current treatments targeting the pathway, and alternative approaches within the pathway that can potentially mitigate proteinase imbalance. LESS Full articleReview|Published on: 9 Dec 2022 -
Foundation for Rare Diseases Annual Scientific Conference: Colloque Scientifique Annuel 2022
Rare Dis Orphan Drugs J 2022;1:14. DOI: 10.20517/rdodj.2022.10Conference Report|Published on: 11 Jul 2022 -
Enzyme replacement therapy: current challenges and drug delivery prospects via extracellular vesicles
Rare Dis Orphan Drugs J 2022;1:13. DOI: 10.20517/rdodj.2022.09Editorial|Published on: 4 Jul 2022 -
Rare diseases: specific challenges for sustainable accessibility of treatments for patients
Rare Dis Orphan Drugs J 2022;1:12. DOI: 10.20517/rdodj.2022.08AbstractIn late 2021, the health technology assessment of the French National Authority for Health was ... MOREIn late 2021, the health technology assessment of the French National Authority for Health was seized by the French Ministry of Solidarity and Health to address a specific challenge, the identification of solutions contributing to the development of the methodological expertise in new types of clinical studies for rare diseases. Experts from the rare diseases environment were gathered by OrphanDev, the French network of expertise dedicated to rare diseases. They allowed to identify some of the current issues in France concerning rare diseases, and then present different solutions, in particular related to the evaluation process of orphan drugs and the collection of data on rare diseases. LESS Full articleTechnical Note|Published on: 8 Jun 2022
See more
About The Journal
-
ISSN
2771-2893 (Online)
Publisher
OAE Publishing Inc.
Article Processing Charges
$600
-
Editor-in-Chief
Daniel Scherman
Publishing Model
Gold Open Access
Copyright
Copyright is retained by author(s)
-
Publication Frequency
Quarterly
Indexing
Journal Data Analysis
Total publications: 17
Total article views: 19,859
Total article downloads: 4,209
Open Archives
-
Portico
All published articles will be preserved here permanently:
https://www.portico.org/publishers/oae/